MX2024002150A - Anticuerpos y proteinas de fusion de igg con una semivida prolongada. - Google Patents
Anticuerpos y proteinas de fusion de igg con una semivida prolongada.Info
- Publication number
- MX2024002150A MX2024002150A MX2024002150A MX2024002150A MX2024002150A MX 2024002150 A MX2024002150 A MX 2024002150A MX 2024002150 A MX2024002150 A MX 2024002150A MX 2024002150 A MX2024002150 A MX 2024002150A MX 2024002150 A MX2024002150 A MX 2024002150A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion proteins
- antibodies
- life
- region
- igg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163235261P | 2021-08-20 | 2021-08-20 | |
| US202163235259P | 2021-08-20 | 2021-08-20 | |
| US202263341443P | 2022-05-13 | 2022-05-13 | |
| PCT/EP2022/073145 WO2023021169A1 (en) | 2021-08-20 | 2022-08-19 | Antibodies and igg fusion proteins with an extended half-life |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002150A true MX2024002150A (es) | 2024-03-08 |
Family
ID=83280226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002150A MX2024002150A (es) | 2021-08-20 | 2022-08-19 | Anticuerpos y proteinas de fusion de igg con una semivida prolongada. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250197514A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4388004A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024531346A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022329459A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3227716A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024002150A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023021169A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026125320A1 (en) | 2024-12-10 | 2026-06-18 | Intervet International B.V. | Caninized il31rα antibodies with an extended half life |
| WO2026125322A1 (en) | 2024-12-10 | 2026-06-18 | Intervet International B.V. | CANINIZED IL31Rα ANTIBODIES WITH AN EXTENDED HALF LIFE |
| WO2026125321A1 (en) | 2024-12-10 | 2026-06-18 | Intervet International B.V. | Caninized il31rα antibodies with an extended half life |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
| US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1673395A1 (en) | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| AU2014368453B2 (en) | 2013-12-20 | 2020-04-16 | Intervet International B.V. | Caninized murine anti-canine PD-1 antibodies |
| EP3526246A1 (en) | 2016-10-17 | 2019-08-21 | Vetoquinol SA | Modified antibody constant region |
| BR112020015006A2 (pt) | 2018-01-26 | 2020-12-29 | Genzyme Corporation | Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada |
| EP3866842A4 (en) | 2018-10-18 | 2022-07-13 | Kindred Biosciences, Inc. | FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE |
| WO2020116560A1 (ja) * | 2018-12-05 | 2020-06-11 | 株式会社バイカ・セラピュティクス | 抗体のFc領域改変体 |
| CN120005022A (zh) * | 2019-01-03 | 2025-05-16 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物及使用方法 |
| KR20220066002A (ko) | 2019-03-20 | 2022-05-23 | 킨드레드 바이오사이언시스, 인코포레이티드 | 의학적 용도의 ngf 길항제 |
| FR3104217B1 (fr) | 2019-12-10 | 2021-12-24 | Innov Shoes | Dispositif d’assemblage amovible entre deux pièces |
| WO2021123092A1 (en) * | 2019-12-20 | 2021-06-24 | Intervet International B.V. | Bispecific caninized antibodies for treating atopic dermatitis |
| JP7832123B2 (ja) | 2020-05-11 | 2026-03-17 | インベテックス インコーポレイテッド | 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法 |
-
2022
- 2022-08-19 WO PCT/EP2022/073145 patent/WO2023021169A1/en not_active Ceased
- 2022-08-19 US US18/684,156 patent/US20250197514A1/en active Pending
- 2022-08-19 MX MX2024002150A patent/MX2024002150A/es unknown
- 2022-08-19 JP JP2024509419A patent/JP2024531346A/ja active Pending
- 2022-08-19 CA CA3227716A patent/CA3227716A1/en active Pending
- 2022-08-19 EP EP22768645.8A patent/EP4388004A1/en active Pending
- 2022-08-19 AU AU2022329459A patent/AU2022329459A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250197514A1 (en) | 2025-06-19 |
| JP2024531346A (ja) | 2024-08-29 |
| CA3227716A1 (en) | 2023-02-23 |
| AU2022329459A1 (en) | 2024-02-29 |
| WO2023021169A1 (en) | 2023-02-23 |
| EP4388004A1 (en) | 2024-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kraft et al. | Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis | |
| US12158473B2 (en) | Multimeric protein purity determination | |
| BR112012006492A2 (pt) | proteína de fusão de anticorpo multivalente, e, ligação de albumina | |
| UA86605C2 (ru) | Антитело, которое содержит вариант исходного человеческого fс-участка | |
| MX2020001707A (es) | Variantes igg fc para uso veterinario. | |
| MY205021A (en) | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof | |
| CY1116863T1 (el) | Πρωτεϊνη δεσμευσης υποδοχεα nogo | |
| EP2352523A4 (en) | IMPROVED ANTI-CD19 ANTIBODIES | |
| JP2021534144A5 (cg-RX-API-DMAC7.html) | ||
| JP2021532114A5 (cg-RX-API-DMAC7.html) | ||
| EA201171259A1 (ru) | Антительные гибридные белки с модифицированными сайтами связывания fcrn | |
| BRPI0507433C1 (pt) | anticorpo monoclonal recombinante ou sua parte de ligação ao antígeno, composição, ácido nucleico isolado, vetor de expressão, e, kit | |
| EA200001023A1 (ru) | Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью | |
| EA200700751A1 (ru) | Способы и композиции для улучшения продуцирования рекомбинантного белка | |
| MA34527B1 (fr) | Anticorps contre la metalloproteinase de matrice 9 | |
| JP2016531546A5 (cg-RX-API-DMAC7.html) | ||
| WO2021047558A1 (zh) | 断裂型内含肽、使用其的重组多肽的制备方法 | |
| JPWO2020116560A1 (ja) | 抗体のFc領域改変体 | |
| PE20230348A1 (es) | Variantes de anticuerpos felinos | |
| WO2021236983A3 (en) | Methods and compositions for protein sequencing | |
| EP4222162A4 (en) | RECOMBINANT FUSION PROTEINS COMPRISING AN INTERLEUKIN-18 BINDING PROTEIN AND A SERUM ALBUMIN ANTIGEN BINDING FRAGMENT, COMPOSITIONS AND USES THEREOF | |
| CO2025012426A2 (es) | Polipéptidos que se unen al receptor de fc neonatal | |
| EA201100741A1 (ru) | Антитела к модифицированным пептидам ифр-1/е человека | |
| KR20220012263A (ko) | 항체의 도메인-특이적 전하 변이체의 특징규명 | |
| MX2023009549A (es) | Compuestos y metodos para prolongar la vida media de biomoleculas. |